Skip to main content
. 2016 Jan 11;127(12):1551–1558. doi: 10.1182/blood-2015-07-657403

Figure 2.

Figure 2

HD daunorubicin is necessary for benefit of the NPM1 mutation. Data for overall survival from the intention-to-treat analysis are shown for patients with NPM1 mutant and NPM1 wild-type AML by receipt of HD daunorubicin or SD daunorubicin.